111 Capital Takes Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

111 Capital bought a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 2,095 shares of the company's stock, valued at approximately $866,000.

Several other institutional investors and hedge funds have also made changes to their positions in IDXX. Geode Capital Management LLC increased its position in IDEXX Laboratories by 1.7% in the 4th quarter. Geode Capital Management LLC now owns 2,297,271 shares of the company's stock valued at $948,279,000 after acquiring an additional 37,734 shares during the period. Bamco Inc. NY increased its position in IDEXX Laboratories by 4.3% in the 4th quarter. Bamco Inc. NY now owns 2,005,522 shares of the company's stock valued at $829,163,000 after acquiring an additional 82,264 shares during the period. Invesco Ltd. increased its position in IDEXX Laboratories by 6.8% in the 4th quarter. Invesco Ltd. now owns 1,160,988 shares of the company's stock valued at $479,999,000 after acquiring an additional 74,324 shares during the period. Norges Bank acquired a new position in IDEXX Laboratories during the 4th quarter worth approximately $412,258,000. Finally, Northern Trust Corp increased its position in IDEXX Laboratories by 18.6% during the 4th quarter. Northern Trust Corp now owns 912,874 shares of the company's stock worth $377,419,000 after purchasing an additional 143,369 shares during the period. 87.84% of the stock is owned by hedge funds and other institutional investors.

IDEXX Laboratories Trading Down 0.6%

Shares of IDXX stock traded down $3.03 on Friday, reaching $512.52. 1,221,827 shares of the stock were exchanged, compared to its average volume of 654,121. The stock has a market cap of $41.22 billion, a P/E ratio of 48.03, a price-to-earnings-growth ratio of 3.41 and a beta of 1.52. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. The firm has a 50 day moving average of $449.80 and a two-hundred day moving average of $437.27. IDEXX Laboratories, Inc. has a 1-year low of $356.14 and a 1-year high of $530.60.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The company reported $2.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.93 by $0.03. IDEXX Laboratories had a return on equity of 55.82% and a net margin of 22.78%. The firm had revenue of $998.43 million during the quarter, compared to the consensus estimate of $998.25 million. During the same period in the prior year, the firm earned $2.71 EPS. The firm's quarterly revenue was up 3.6% compared to the same quarter last year. On average, research analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Analysts Set New Price Targets

IDXX has been the topic of several recent analyst reports. Stifel Nicolaus boosted their target price on IDEXX Laboratories from $460.00 to $510.00 and gave the stock a "hold" rating in a research report on Monday, May 19th. Bank of America boosted their target price on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a "neutral" rating in a research report on Tuesday, February 4th. Wall Street Zen upgraded IDEXX Laboratories from a "hold" rating to a "buy" rating in a research report on Thursday, May 22nd. Morgan Stanley boosted their target price on IDEXX Laboratories from $548.00 to $558.00 and gave the stock an "overweight" rating in a research report on Monday, May 5th. Finally, Barclays boosted their target price on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 4th. Three investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $536.00.

Insider Activity

In other news, Director M Anne Szostak sold 1,046 shares of the firm's stock in a transaction dated Wednesday, May 21st. The stock was sold at an average price of $513.74, for a total transaction of $537,372.04. Following the completion of the sale, the director now directly owns 262 shares in the company, valued at $134,599.88. This trade represents a 79.97% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.98% of the company's stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.